Lilly Unveils New Glycopeptides

2 April 1995

The recent upsurge in vancomycin-resistant enterococci has encouraged the search for new agents to treat these infections. Eli Lilly says it has developed a series of glycopeptide drugs from a parent compound (LY264826), which have the unusual property of being bactericidal against enterococci.

These derivatives are active against resistant enterococci strains, as well as a broad range of other Gram positive organisms including resistant strains of staphylococci and pneumococci. They were developed as part of an extensive screening program at Lilly.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight